Open Access Articles- Top Results for Bradanicline


Systematic (IUPAC) name
N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
Clinical data
PubChem CID 16727410
UNII UM3821998K 7pxY
Synonyms TC-5619
Chemical data
Formula C22H23N3O2
361.437 g/mol
 14pxY (what is this?)  (verify)

Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [1] Phase I clinical trials were completed successfully, and it was in phase II trials.[2]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[3] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[4] It was being studied for cognitive and memory enhancement.[5]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[6] It was also discontinued for ADHD, and no longer seems to be being developed.[6]


Template:Navbox with collapsible sections

Lua error in package.lua at line 80: module 'Module:Buffer' not found.